UK-based Genetix has completed the acquisition of Applied Imaging (San Jose, USA)
Through the integration of Genetix breakthrough cell biology platforms (ClonePix FL and CloneSelect Imager) and Applied Imaging's Ariol and CytoVision product lines, the company can now deliver systems that track the progress of drug discovery from the research laboratory through to the clinic.
ClonePix FL and CloneSelect Imager, along with their dedicated reagents and consumables, have revolutionised the generation, selection and management of mammalian cell lines for biopharmaceutical and drug discovery.
Eliminating laborious manual procedures and screening very large numbers of cells rapidly, Genetix systems shorten timescales from weeks to days.
Cell culture is simplified, turning large scale, high throughput screening from a facility-based activity into a benchtop process.
The Ariol pathology instrumentation and the CytoVision software, enable the nature of tumours to be studied at protein biomarker level.
This is invaluable in the drug discovery process - for target discovery and as a monitor of therapeutic response and predictor of treatment effectiveness.
